bexarotene has been researched along with Androgen-Independent Prostatic Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, J; Chang, C; He, X; Hu, L; Li, G; Luo, J; Sun, Y; Ye, M; Zhang, D; Zhang, Y | 1 |
| Dar, JA; Eisermann, K; Feturi, FG; Johnston, PA; Kenefake, AN; Masoodi, KZ; Nelson, JB; Nguyen, M; O'Malley, K; Parrinello, E; Pascal, LE; Wang, Z; Wipf, P; Yang, Z | 1 |
| Af Hällström, TM; Aittokallio, T; Bychkov, D; Eldfors, S; Heckman, C; Horvath, P; Kallioniemi, O; Mirtti, T; Mpindi, JP; Östling, P; Paavolainen, L; Peehl, DM; Rahkama, V; Rannikko, A; Saeed, K; Wennerberg, K; Yadav, B | 1 |
3 other study(ies) available for bexarotene and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
Topics: Antineoplastic Agents; Apoptosis; Bexarotene; Biomarkers, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Steroid; Receptors, Thyroid Hormone; Tumor Cells, Cultured | 2020 |
Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Topics: Androgen Receptor Antagonists; Animals; Benzamides; Bexarotene; Binding Sites; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Nitriles; Phenylthiohydantoin; Piperazines; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2017 |
Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Bexarotene; Cellular Reprogramming Techniques; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Kallikreins; Keratin-18; Keratin-5; Male; Organoplatinum Compounds; Oxaliplatin; Precision Medicine; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinacrine; Receptors, Androgen; Sulfonamides; Tetrahydronaphthalenes; Tretinoin; Tumor Cells, Cultured | 2017 |